SCHEMBL31435243

SCHEMBL31435243

COC(=O)[C@H]1CCN(Cc2noc(-c3ccc(F)c(C(F)(F)F)c3)n2)[C@@H](C)C1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 13/20 0.41
ACKR3 P25106 2/20 0.38
DYRK3 O43781 1/20 0.36
MAP4K4 O95819 1/20 0.36
ERBB2 P04626 1/20 0.36
PIM1 P11309 1/20 0.36
MARK3 P27448 1/20 0.36
PLK1 P53350 1/20 0.36
CAMK2B Q13554 1/20 0.36
CDC42BPA Q5VT25 1/20 0.36
PIM3 Q86V86 1/20 0.36
MINK1 Q8N4C8 1/20 0.36
SRPK1 Q96SB4 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
MAP3K20 Q9NYL2 1/20 0.36
MAP4K5 Q9Y4K4 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CNR2 P34972 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31435253 0.91 S1PR1 (0.46) S1PR1DYRK3MAP4K4ERBB2PIM1
SCHEMBL31435263 0.91 S1PR1 (0.46) S1PR1DYRK3MAP4K4ERBB2PIM1
SCHEMBL31435222 0.84 UBE2M (0.46) ACKR3ALDH1A1
SCHEMBL31435230 0.84 ACKR3 (0.46) S1PR1ACKR3
SCHEMBL31435258 0.84 ACKR3 (0.46) S1PR1ACKR3
SCHEMBL31435225 0.84 UBE2M (0.46) ACKR3ALDH1A1
SCHEMBL31435231 0.84 UBE2M (0.46) ACKR3ALDH1A1
SCHEMBL31435267 0.83 GSK3B (0.43) S1PR1ACKR3
SCHEMBL31435264 0.83 ACKR3 (0.42) S1PR1ACKR3
SCHEMBL31435252 0.83 ACKR3 (0.38) S1PR1ACKR3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025090928-A9 COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES AQUINNAH PHARMACEUTICALS, INC. (US) 2026-04-30 WO disclosed
WO-2025090928-A1 COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES AQUINNAH PHARMACEUTICALS, INC. (US) 2025-05-01 WO disclosed